Life Insurance With Connective Tissue Disorders in Canada
Find clear, brokered paths to coverage with affordable options, expert underwriting guidance, and Canada-wide support for connective tissue disorders such as Ehlers-Danlos, Marfan, and lupus.
📖 13 minute read
📅 Originally Published: March 8, 2023
🔄 Updated: October 22, 2025
Life Insurance With Connective Tissue Disorders in Canada
Find clear, brokered paths to coverage with affordable options, expert underwriting guidance, and Canada-wide support for connective tissue disorders such as Ehlers-Danlos, Marfan, and lupus.
📖 13 minute read
📅 Originally Published: March 8, 2023
🔄 Updated: October 22, 2025
If you live with a connective tissue disorder, getting life insurance can feel complicated. This guide explains how Canadian insurers review CTDs, what documentation helps, and when to consider simplified or guaranteed issue policies so you can protect the people who count on you.
You will learn how insurers assess Ehlers-Danlos syndrome, Marfan syndrome, and lupus, plus practical steps to improve approval outcomes such as submitting recent specialist reports and up-to-date imaging. We also outline when critical illness or disability insurance may be a better first step while you build a stronger life application.
In this article
- Overview: Connective Tissue Disorders & Life Insurance in Canada
- Lifestyle & Medical Triggers That Impact Approval
- How Canadian Underwriters Assess Connective Tissue Disorders
- Underwriting Factors for Connective Tissue Disorders
- Policy Options in Canada
- Likely Approval Outcomes & Pricing Scenarios
- Canadian Insurer Tendencies
- Timing Your Application & Alternatives
- Documentation & Advisor Communication Tips
- Practical Ways to Improve Approval Odds
- Frequently Asked Questions
- Case Studies
- Get Personalized Advice & Quotes
Overview: Connective Tissue Disorders & Life Insurance in Canada
Connective tissue disorders (CTDs) are genetic or acquired conditions that affect the tissues supporting the skin, joints, bones, blood vessels, and organs. Common examples include Ehlers-Danlos syndrome (EDS), Marfan syndrome, osteogenesis imperfecta, and systemic lupus erythematosus (SLE). Symptoms range from joint hypermobility and chronic pain to organ involvement. From an insurance perspective, the focus is on clinical stability, complication history, and specialist oversight because these drive long-term risk and pricing.
If you are exploring life insurance with connective tissue disorders in Canada, approvals are possible. Outcomes depend on the specific diagnosis and severity, evidence of control, and any cardiovascular or organ risks. For example, insurers look closely at aortic dimensions in Marfan, arterial fragility in some EDS subtypes, and renal or cardiac involvement in lupus. Stable cases with regular follow-up often qualify for traditional coverage, while complex histories may be better served by simplified or guaranteed options. For overlapping concerns, readers often review heart-related context in our guide on life insurance with heart conditions.
What underwriters want to see
- Recent specialist notes (rheumatology, cardiology, genetics) confirming diagnosis, subtype if applicable, and current status.
- Key test results with dates (e.g., echocardiogram and aortic root measurements), relevant imaging, pulmonary function when indicated, and lab markers of disease activity.
- Medication list and adherence, including biologics, immunosuppressants, or pain management plans.
- History of surgeries, hospitalizations, or flare-ups, plus current rehabilitation or physiotherapy.
Why this matters for approval and pricing
- Documented stability over time and predictable follow-up often lead to more favourable decisions.
- Active complications, recent surgeries, or uncontrolled symptoms can result in ratings, exclusions, or temporary postponement while records are updated.
- Clear documentation and coordinated care reduce uncertainty, which can improve both approval odds and premiums.
Those navigating CTDs sometimes manage related gastrointestinal issues; our overview on life insurance with Crohn’s disease provides context for underwriting questions that may surface during review. This foundation sets up the next sections on how underwriters assess applications, which policy types work best, and practical steps to strengthen your file.
Lifestyle & Medical Triggers That Impact Approval
Medical triggers underwriters flag
- Aortic root diameter or rapid change (Marfan and some EDS subtypes): recent echo findings, z-scores, and surgical history materially affect eligibility and pricing.
- Arterial or organ fragility: history of tears/ruptures, spontaneous pneumothorax, or vascular complications increases scrutiny and can lead to ratings or postponement.
- Active inflammation or frequent flares (e.g., SLE): elevated disease activity, hospitalizations, or steroid bursts signal instability and may pause traditional underwriting until control is demonstrated. See our context on overlapping autoimmune risk in life insurance with lupus.
- Medication profile: long-term high-dose corticosteroids, immunosuppressants/biologics, anticoagulants, or complex pain regimens often trigger additional questionnaires.
- Imaging and test gaps: outdated echocardiograms, missing genetics consults, or absent specialist letters add uncertainty that typically prices in as a rating.
Lifestyle and history signals
- Tobacco or vaping use: any nicotine within the testing window typically shifts pricing to smoker rates; cannabis patterns are reviewed case-by-case.
- High-impact or contact activities: powerlifting, gymnastics, combat sports, or jobs with heavy physical strain raise concern for joint/vascular injury in CTDs.
- Driving and occupational risk: commercial driving, remote work sites, or hazardous duties can add non-medical risk factors to the file.
- Comorbid conditions: sleep apnea, hypertension, dyslipidemia, and GI involvement (e.g., malabsorption) can compound mortality assumptions. Readers sometimes cross-check GI considerations in our Crohn’s guide.
- Follow-up consistency: missed specialist appointments or irregular lab/echo intervals suggest poor surveillance and may delay offers until continuity is shown.
Practical thresholds that change decisions
- Recent surgeries or ER visits (past 6–12 months): many carriers postpone until recovery milestones and fresh notes are available.
- Objective stability window: 12–24 months without major complications, documented by specialists, often unlocks consideration for standard or mildly rated offers.
- Documentation depth: a concise cover letter plus the latest echo/imaging, medication list, and specialist summary can reduce underwriter queries and shorten timelines.
Bottom line: approvals hinge on risk signals that underwriters can quantify. Tight follow-up, updated imaging, and clear specialist oversight reduce uncertainty and keep pathways open to traditional coverage; when instability is present, the file may shift temporarily toward simplified or guaranteed solutions before revisiting full underwriting.
How Canadian Underwriters Assess Connective Tissue Disorders
The underwriting workflow at a glance
Canadian carriers follow a similar sequence: application intake → evidence review → risk stratification → decision (approve, rate, exclude, or postpone). For connective tissue disorders (CTDs), the emphasis is on objective stability, organ/cardiovascular involvement, and quality of follow-up. Expect a blend of application questions, digital health checks, and when warranted, attending physician statements (APS), imaging, and recent specialist notes (rheumatology, cardiology, genetics).
Evidence underwriters typically request
- Recent specialist letters confirming diagnosis and subtype (e.g., vascular EDS, Marfan), current status, and next follow-up interval.
- Test results with dates: echocardiogram (aortic root size and z-scores for Marfan spectrum), relevant vascular or musculoskeletal imaging, pulmonary function if respiratory complications are suspected, and lab markers of disease activity in autoimmune CTDs (e.g., SLE).
- Medication profile and response: biologics or immunosuppressants, steroid exposure (dose and duration), anticoagulants, pain regimens, and any side-effect monitoring.
- Event history: surgeries, ER visits, pneumothorax, arterial events, fracture frequency (for OI), and hospitalizations in the past 12 to 24 months.
- Functional snapshot: work capacity, rehab or physio, activity restrictions, and adherence to recommended surveillance (echo cadence, genetics follow-up).
How risk is stratified for common CTDs
- Marfan spectrum: aortic dimensions and rate of change, surgical history (e.g., root repair), beta-blocker or ARB use, and blood pressure control are central. Stable post-op cases with predictable follow-up can be assessed more favourably.
- EDS (including vascular subtypes): evidence of arterial fragility, organ rupture, significant hernias or wound-healing issues, and frequency of acute events guide decisions. Non-vascular subtypes with mild manifestations may receive more traditional consideration.
- SLE: organ involvement (renal, cardiac, CNS), flare frequency, steroid burden, and immunosuppressant response carry more weight than diagnosis alone. Long periods of quiescence with specialist oversight are advantageous. Readers often cross-reference our Canadian overview for nuances in life insurance with lupus.
- Osteogenesis imperfecta: fracture pattern, severity classification, surgical hardware, and mobility or respiratory status influence offers. Documentation of stability and fall-risk mitigation helps.
Typical requirement tiers
- Low complexity and stable: application data plus e-records. Paramed may be waived depending on age and amount.
- Moderate complexity: APS plus recent imaging (e.g., echo), with possible fluids and ECG based on age or face amount and carrier rules.
- Higher risk or recent events: postponement until new imaging or specialist reassessment confirms stability. Some files pivot to simplified or guaranteed coverage while monitoring continues. See related context in our piece on life insurance with heart conditions when cardiovascular reviews are central.
Decision levers that change outcomes
- Fresh, complete documentation reduces uncertainty and can turn a tentative rating into standard or mildly rated terms.
- Time since the last significant complication (for example, surgery or hospitalization) often dictates whether a case proceeds now or is temporarily postponed pending recovery milestones.
- Demonstrated adherence (medication, follow-ups, rehab) is weighed positively and can offset diagnosis-level concerns.
Bottom line: underwriters are looking for predictability. When CTD care is coordinated and supported by up-to-date tests, many Canadian carriers will consider traditional coverage. Where uncertainty is higher, a staged approach that starts with simplified and revisits full underwriting after stability is documented can preserve affordability and continuity.
Underwriting Factors for Connective Tissue Disorders
What actually moves the decision
Underwriters center on three signals: clinical stability, organ or cardiovascular involvement, and evidence quality. A file with current imaging, clear specialist notes, and steady medications is easier to price than a file with gaps or recent events.
- Medical signals: aortic root size and trend, vascular or organ fragility, flare frequency, steroid burden, hospitalizations in the past 12 to 24 months, and functional status.
- Non-medical signals: nicotine or vaping use, BMI and blood pressure, hazardous duties or high-impact activities, and disclosure consistency.
If heart surveillance is central, many readers skim our primer on life insurance with heart conditions to anticipate tests and follow up intervals that often shape CTD outcomes.
Table 1: Risk Factors and Advisory Considerations for CTD Applicants
How lifestyle and medical factors influence underwriting outcomes in Canada.
| Risk Factor | How Insurers View It | Advisory Consideration |
|---|---|---|
| Aortic root size or rapid change (Marfan spectrum) | Primary mortality signal; drives ratings, may trigger postponement if trending unfavourably | Provide latest echo with dates and z-scores; include cardiology plan and next follow-up |
| Vascular/organ fragility events (e.g., vascular EDS, spontaneous pneumothorax) | High-severity red flag; recent events often pause traditional underwriting | Submit operative reports/discharge summaries; show stabilization period before re-apply |
| SLE disease activity and steroid burden | Active flares or high-dose/long-term steroids suggest instability | Document quiescence window and taper history; include rheumatology notes and labs |
| Recent surgeries or ER visits (last 6–12 months) | Signals ongoing risk or incomplete recovery | Wait for surgeon/specialist clearance; add updated imaging before resubmitting |
| Medication profile (biologics, immunosuppressants, anticoagulants) | Neutral to positive if control is good; negative if frequent changes/side effects | List doses/dates and response; attach monitoring plans to show stability |
| Functional status and rehab/physio adherence | Improved function reduces perceived risk and uncertainty | Include physio notes and work capacity details in APS cover letter |
| Nicotine or vaping use | Almost always priced at smoker rates regardless of diagnosis | Observe carrier testing windows; disclose accurately to avoid contestability issues |
| High-impact sports / hazardous duties | Elevates injury/rupture risk in CTDs; may add ratings or exclusions | Describe risk-mitigation steps and any activity modifications |
| BMI and blood pressure control | Adverse vitals compound cardiovascular assumptions | Provide recent vitals trend; note lifestyle changes and medication adherence |
| Documentation gaps (outdated imaging, missing specialist letters) | Uncertainty increases price or delays decisions | Create a concise evidence packet: latest echo/imaging, APS summary, meds list |
- Aortic root change: Key risk → Share latest echo, z-scores, and cardiology plan.
- Vascular/organ events: Recent issues pause cases → Provide op notes and stabilization proof.
- SLE activity/steroids: Active disease hurts offers → Show quiescence and taper history.
- Recent surgery/ER: Often postponement → Re-apply after clearance and new imaging.
- Medications: Stable control helps → Include doses, dates, monitoring plan.
- Function/rehab: Better function helps → Add physio notes and work capacity.
- Nicotine/vaping: Smoker rates likely → Respect testing windows, disclose fully.
- High-impact duties: Raises injury risk → Note mitigation and modifications.
- BMI/BP: Poor control compounds risk → Provide recent vitals trend.
- Doc gaps: Uncertainty ↑ price/time → Send a complete evidence packet.
Policy Options in Canada
Pick the product that fits the evidence
Choose based on stability, budget, and timeline. Traditional term or permanent works best when testing is current and complications are quiet. When evidence is pending, simplified or guaranteed coverage can protect the plan until new milestones are reached.
- Term: cost efficient for liabilities and family protection.
- Permanent: lifelong needs with cash value potential.
- Simplified: short questionnaire and fast decisions while you update imaging or notes.
- Guaranteed: lower face amounts that keep some protection in place during recovery.
Where GI overlap affects nutrition or weight, our overview on life insurance with Crohn’s disease helps set expectations for documentation.
Table 2: Policy Options for CTD Applicants
How product types align with common underwriting scenarios in Canada.
| Policy Type | Best For | Underwriting Lens | Advisor Notes |
|---|---|---|---|
| Term life | Mortgage and income protection over 10 to 30 years | Favourable when there is documented stability, current imaging, and predictable follow-up | Pick a term that matches liabilities. Prepare a concise evidence packet to reduce queries. |
| Whole life | Lifelong protection with cash value accumulation | Similar stability requirements to term. Ratings more likely than exclusions for controlled CTDs | Consider smaller base now with paid-up additions later once new tests confirm stability. |
| Universal life | Flexible premiums and long-term planning | Requires clear surveillance cadence and good adherence to care plans | Use level cost of insurance for predictability if budget sensitivity is high. |
| Simplified issue | Interim coverage when traditional underwriting is delayed | No exams. Health questions still apply, yet decisions are faster | Layer now and revisit full underwriting after updated echo or specialist reassessment. |
| Guaranteed issue | Recent surgery or active complications that block traditional review | No health questions. Graded death benefit and lower face amounts | Use as a short-term safety net. Replace or supplement once stability is documented. |
| Critical illness | Lump sum for covered conditions that may overlap with CTD risks | Carrier definitions and exclusions vary. Evidence of control still matters | Coordinate with life coverage so total budget remains sustainable. |
| Disability insurance | Income protection where function and recovery timelines are central | Focus on occupation class, restrictions, and claims history | Document rehab participation and workplace accommodations to support eligibility. |
- Term: Good for mortgages and income. Works best with stable findings and current tests.
- Whole: Lifelong coverage with cash value. Ratings possible when control is documented.
- Universal: Flexible but needs consistent surveillance and adherence.
- Simplified: Fast interim option while gathering new imaging or letters.
- Guaranteed: Safety net when traditional is blocked. Often graded and lower face amounts.
- Critical illness: Lump sum for covered conditions. Coordinate with life premiums.
- Disability: Income protection that depends on occupation class and function.
Likely Approval Outcomes and Pricing Scenarios
How decisions are formed
Outcomes reflect stability over time, extent of organ involvement, and documentation quality. Clean evidence supports standard or mild ratings. Recent surgery, active flares, or missing tests can lead to postponement or alternative issuance.
- Standard or near standard: stable findings, current imaging, regular follow up.
- Rated: residual risk that is documented and predictable.
- Postponed: recent events that require the next scan or specialist review.
- Alternative: simplified or guaranteed coverage while evidence is refreshed.
A short cover note that lists time since the last event, key measurements, medication stability, and next appointments often improves pricing. For autoimmune overlap, see life insurance with lupus to understand how quiescence affects offers.
Table 3: CTD Scenarios and Likely Outcomes
Illustrative decisions with one actionable next step.
| Profile | Likely Outcome | Next Step |
|---|---|---|
| Marfan stable for 24 months with routine cardiology | Standard to moderate rating | Send latest echo and cardiology letter with next review date |
| Post-op Marfan with clean follow-up imaging | Moderate rating | Attach surgeon clearance and most recent imaging |
| Vascular EDS with recent arterial event | Postponed | Use simplified coverage and reapply after specialist reassessment |
| SLE in long quiescence with low steroid exposure | Standard to moderate rating | Provide rheumatology summary, labs, and medication list |
| Non-vascular EDS with musculoskeletal symptoms only | Standard to mild rating | Include physio notes and confirm no recent acute events |
- Marfan stable: standard to moderate → send echo and note.
- Post-op Marfan: moderate → add clearance and imaging.
- Vascular EDS recent event: postponed → use simplified, then reapply.
- SLE quiescent: standard to moderate → include summary, labs, meds.
- EDS non-vascular: standard to mild → add physio notes and history.
Canadian Insurer Tendencies
How carriers often approach CTD files
Canadian carriers share a common lens. They value predictable surveillance, current imaging, and clear specialist oversight. Differences show up in comfort with recent surgeries, use of ratings versus postponements, and availability of simplified or guaranteed on-ramps when traditional underwriting is not ideal. When cardiovascular review is central, applicants often benefit from the context in our guide on life insurance with heart conditions.
Table 4: Carrier Tendencies for CTD Applicants
High level patterns that can help match a CTD profile to a Canadian insurer.
| Insurer | Observed Tendency | Practical Submission Tip |
|---|---|---|
| Manulife | Emphasis on recent imaging and clear recovery timelines for cardiac or vascular involvement | Attach the latest echo with measurements and a cardiology letter that states next follow up |
| Canada Life | Structured use of ratings where stability is documented and risk is quantifiable | Provide a short cover note that outlines time since last event and medication stability |
| RBC Insurance | Straightforward file handling when evidence is current and surveillance cadence is predictable | Bundle APS summary, imaging dates, and upcoming specialist appointments on one page |
| iA Financial Group | Close attention to functional status and return to work after surgery or complications | Include physio notes and a work capacity statement with any restrictions or accommodations |
| Empire Life | Pragmatic on well documented stability with modest residual risks | Show a two year stability window if available and list any flare prevention strategies |
| Foresters Financial | Useful simplified options when traditional underwriting is temporarily out of reach | Position as a bridge while you obtain updated imaging or specialist reassessment |
| Beneva | Detail oriented on recent events and medication adjustments | Note dose changes with dates and provide the monitoring plan that supports control |
| Assumption Life | Access to simplified and guaranteed pathways for complex or recent cases | Use simplified for near term protection and schedule a future review once tests are current |
- Manulife: imaging and timelines matter → send echo and cardiology note.
- Canada Life: ratings for documented stability → add a brief cover note.
- RBC: predictable surveillance helps → bundle APS, imaging dates, next visits.
- iA: function and return to work → include physio notes and capacity.
- Empire Life: stable two year history is strong → outline flare prevention.
- Foresters: simplified bridge when needed → revisit after new imaging.
- Beneva: track med changes → include doses, dates, and monitoring plan.
- Assumption Life: simplified or guaranteed paths → plan future review.
Timing Your Application and Alternatives
Make timing work for you
Good outcomes often come from the right timing. Underwriters respond well to fresh evidence, clear stability, and predictable follow up. Apply when your most important tests are current and your specialist notes confirm control. If a major review is coming up, consider a short delay so the file includes that result. Where cardiovascular monitoring is central, many readers first skim our guide on life insurance with heart conditions to plan echo cadence and documentation.
When to apply now
- Stable for 12 to 24 months with routine specialist care and no recent ER visits or surgeries.
- Imaging and labs are dated within the carrier window that your advisor expects for your age and face amount.
- Medication plan is steady and side effects are monitored with notes in the chart.
When to postpone and bridge
- Pending echo or key imaging that will likely resolve uncertainty.
- Recent surgery or flare that needs a recovery milestone or a specialist clearance.
- Significant medication change that needs a few months of stable response.
Alternatives that keep protection in place
- Simplified issue for fast decisions while you complete tests.
- Guaranteed issue if traditional is not available due to very recent events.
- Layering with critical illness or disability to stabilize cash flow during treatment. See context in our article on life insurance with Crohn’s disease when GI overlap affects nutrition or weight.
Table 5: Timing and Alternative Paths for CTD Applicants
Quick cues for when to apply now versus bridge and revisit.
| Situation | Best Timing | Alternative Path | Advisor Note |
|---|---|---|---|
| Stable CTD with current imaging and steady meds | Apply now | Traditional term or permanent | Bundle echo or imaging dates and a brief cover note |
| Pending echo or specialist reassessment | Wait for results | Simplified issue for interim coverage | Resubmit with the new report and next follow up date |
| Recent surgery or ER visit | After clearance and recovery milestone | Guaranteed issue if protection is needed immediately | Include discharge summary and surgeon clearance |
| Medication change or steroid taper underway | After several months of documented stability | Simplified issue then replace when stable | Show dose history and monitoring plan |
| Multiple comorbidities with outdated tests | After evidence refresh | Layer CI or DI while updating records | Provide a checklist of tests and dates to complete |
- Stable with current tests: apply now. Include a brief cover note.
- Pending echo: wait for results. Use simplified in the meantime.
- Recent surgery: apply after clearance. Guaranteed can fill the gap.
- Med change or taper: wait for stability. Replace simplified later.
- Outdated tests: refresh evidence. Layer CI or DI during updates.
Documentation and Advisor Communication Tips
Build a clean evidence packet
Stronger outcomes come from current tests, clear specialist summaries, and simple organization. Use one concise cover page, then attach the most recent imaging and letters. If cardiovascular review is relevant, this overview of heart tests from the Heart and Stroke Foundation of Canada can help you anticipate what underwriters expect.
What to include up front
- Specialist letters that confirm diagnosis and subtype, current status, treatment plan, and next appointment date.
- Imaging and tests with dates. For example, echo with aortic measurements, vascular or musculoskeletal imaging, pulmonary function when applicable, and labs for autoimmune activity.
- Medication list with dose and start dates, plus notes on response and monitoring for side effects.
- Event timeline for surgeries, ER visits, or hospitalizations in the past 12 to 24 months and today’s recovery status.
- Function snapshot that outlines work capacity, restrictions, and physio or rehab participation.
How to communicate with your advisor
- Use a short cover note that highlights stability window, key measurements, and the next follow up.
- Flag pending tests and when results will be available so timing can be planned.
- Keep answers consistent with physician records to avoid delays.
Practical Ways to Improve Approval Odds
Small steps that change outcomes
- Refresh key tests before you apply. For Marfan spectrum, include the latest echo with aortic measurements and comparison to prior results.
- Document stability over a clear window. List flare frequency, surgeries, and hospitalizations with dates and recovery status.
- Tidy your medication story. Show dose history, response, and side effect monitoring for biologics, immunosuppressants, or steroids.
- Show consistent follow up with cardiology, rheumatology, or genetics. Include the next appointment date to demonstrate predictable surveillance.
- Address lifestyle signals. Non-smoker status, blood pressure control, and activity modifications reduce uncertainty in CTD files.
Make the file easy to underwrite
- Provide a one page cover note that summarizes diagnosis and subtype, stability window, key measurements, and next milestones.
- Bundle evidence in logical order. Put the cover note first, then specialist letters, then imaging, then labs, then the medication list.
- Where GI overlap affects nutrition or weight, add context with our overview on life insurance with Crohn’s disease so the reviewer understands the plan of care.
FAQ – Frequently Asked Questions
Can I get life insurance if I have a connective tissue disorder?
Yes. Approvals are possible when your file shows clinical stability, current tests, and specialist oversight. Traditional coverage is common for stable cases. When evidence is pending, simplified or guaranteed options can bridge coverage until new results are available.
What factors do insurers consider for CTD applications?
Underwriters review diagnosis and subtype, organ or cardiovascular involvement, flare frequency, medication burden, recent surgeries or hospitalizations, nicotine status, and follow up consistency. Our overview of life insurance with heart conditions explains why a current echocardiogram can be important for some CTD profiles.
What types of policies are available for people with CTDs?
You can consider term or permanent coverage when stability is documented. If recent events create uncertainty, simplified issue or guaranteed issue can provide protection while you complete testing. Coordinating with critical illness or disability insurance can support cash flow during treatment.
Will my premiums be higher because of a CTD?
They can be. Pricing reflects residual risk and uncertainty. Clean documentation that confirms stability can result in standard or mildly rated offers. Recent complications, active flares, or missing tests can lead to higher ratings or temporary postponement.
What should I do if I am declined or postponed?
Ask for the reason and timeline. Many cases improve once new imaging or specialist notes arrive. Consider simplified coverage during the waiting period, then reapply with an updated evidence packet that includes dates and measurements.
How do Ehlers Danlos subtypes affect underwriting?
Non vascular subtypes with musculoskeletal symptoms only may receive traditional consideration when stable. Vascular EDS requires careful review of arterial or organ events. Provide specialist letters, any operative notes, and a clear stability window.
What do insurers focus on for Marfan syndrome?
Underwriters look at aortic root size and trend, medication use such as beta blockers or ARBs, and surgical history. Include the latest echocardiogram with dates and measurements, plus cardiology follow up plans. Context in our heart conditions guide can help set expectations: life insurance with heart conditions.
How does lupus (SLE) influence approval?
Decision makers consider organ involvement, flare frequency, and steroid burden. Long quiescence with specialist oversight is favourable. See our Canada focused article for added context: life insurance with lupus.
What documents should I include with my application?
A concise cover note, the most recent specialist letters, imaging with dates, lab results that show disease control when applicable, medication list with dose and start dates, and a short event timeline that covers surgeries or ER visits in the last 12 to 24 months.
Can I apply soon after surgery or an ER visit?
Most carriers prefer a recovery milestone and a clearance note. If protection is needed immediately, consider simplified or guaranteed coverage, then revisit traditional underwriting once new tests confirm stability.
Does nicotine or vaping status change the decision?
Yes. Nicotine use is usually priced at smoker rates. Disclose status accurately and plan for a non smoker review when criteria are met.
Are provincial differences important for CTD life insurance?
Underwriting is national. Provincial references are more relevant for availability of specialists and testing timelines rather than policy rules. Internal navigation to related topics can help you prepare, for example life insurance with Crohn’s disease when GI overlap is present.
Case Studies
Profile: Marfan spectrum. Non smoker. On ARB therapy. Routine cardiology follow up.
- Problem: Concern that aortic root history would block traditional term coverage.
- Approach: Submitted the latest echo with measurements and a cardiology letter that listed the next review date. Selected a carrier that values predictable surveillance, guided by our insights from life insurance with heart conditions.
- Resolution: Approved at moderate rating for a 20 year term, with a plan to review pricing after the next stable echo.
Takeaway: Clear imaging with dates and a follow up plan can shift a tentative file into a competitive term offer.
Profile: SLE with long quiescence. Low steroid exposure. Desk based occupation.
- Problem: Wanted permanent coverage but worried that a past flare would trigger a postponement.
- Approach: Provided a rheumatology summary, labs indicating control, and a simple medication table. Considered term plus a smaller permanent base, with the intention to scale after the next review. For background she referenced life insurance with lupus.
- Resolution: Near standard permanent base approved, layered with term to reach the total need. Plan to reassess after the next annual specialist visit.
Takeaway: Long quiescence plus concise evidence can support permanent coverage, and layering keeps budget predictable.
Find a solution for what you’re looking for
Life insurance with connective tissue disorders is crucial to provide financial protection for loved ones in case of unexpected events. It can give peace of mind knowing that the future of loved ones is secure even if the individual with CTDs passes away or becomes unable to work. Protect Your Wealth can help you get it by guiding you through the process of buying life insurance and determining your needs!
To schedule a consultation about your income protection goals, or if you have any questions about insurance in Ontario or Canada, please contact Protect Your Wealth or call us at 1-877-654-6119 to talk to an advisor today! We’re proudly based out of Hamilton, and service clients anywhere in Ontario, British Columbia and Alberta including areas such as Kingston, Guelph, Calgary, and Coquitlam.
